Marshall, Catherine Handy
Fu, Wei
Wang, Hao
Baras, Alexander S.
Lotan, Tamara L.
Antonarakis, Emmanuel S.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA006973)
Article History
Received: 4 June 2018
Revised: 19 July 2018
Accepted: 31 July 2018
First Online: 31 August 2018
Compliance with ethical standards
:
: Emmanuel S. Antonarakis is a paid consultant/advisor to Janssen, Astellas, Sanofi, Medivation, ESSA, AstraZeneca, Clovis and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Tokai and Qiagen. Catherine Handy Marshall received research support through the Conquer Cancer Foundation/Bristol Meyers Squibb. The remaining authors declare that they have no conflict of interest.